department of obstetrics of Second Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, 325027, China
NCT Number: NCT04777929
Phthalates are a group of ubiquitous synthetic endocrine-disrupting chemicals. Fetal and neonatal periods are particularly susceptible to endocrine disorders, which prenatal exposure to phthalates causes. There is increasing evidence concerning the potential endocrine disrupting for phthalate exposure during pregnancy. Prenatal exposure phthalates would disrupt the level of sex hormone in pregnant women, which results in preeclampsia. The relationship of prenatal phthalate exposure with maternal and neonatal outcomes in human beings was often sex-specific associations. Because of the potentially harmful influence of prenatal phthalate exposure, steps should be taken to prevent or reduce phthalate exposure during pregnancy.
Looking for future studies?
Notify Me18 year–40 year
Female
Observational
Wenzhou, Zhejiang, 325027, China
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
test mothers Phthalates in their urine, and test estrogen and progesterone receptor in placental tissue
Time frame: 37 weeks to 40 weeks gestation
Collect the urine of pregnant women and test the abundance of Phthalates
Time frame: 37 weeks to 40 weeks gestation
Collect the placenta tissue of pregnant women and test the abundance of estrogen progesterone receptor
Second Affiliated Hospital of Wenzhou Medical University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05864209
Bisphenol Exposure, Phthalate Exposure
Brooklyn, New York, United States
View Trial DetailsNCT05780047
Bisphenol A, Endocrine Disrupting Chemicals
Berkeley, California, United States
View Trial DetailsNCT05802940
Aspirin, Behavior
Danville, Pennsylvania, United States
View Trial DetailsNCT07717931
Cardiovascular Diseases, Female Urogenital Diseases and Pregnancy Complications
Multan, Punjab Province, Pakistan
View Trial Details